Vireo Growth (VREOF) Total Liabilities (2020 - 2026)
Vireo Growth (VREOF) posted Total Liabilities of $634.7 million for Q1 2026, up 24.5% sequentially from $509.8 million in Q4 2025, and up 180.09% YoY from $226.6 million in Q1 2025.
Vireo Growth (VREOF) Total Liabilities (2020 - 2026) Analysis & Trends
Vireo Growth has reported Total Liabilities for 7 years, with the latest figure at $634.7 million in Q1 2026.
- Quarterly Total Liabilities rose 180.09% year-over-year to $634.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $634.7 million (up 180.09% YoY) and the FY2025 annual result came in at $509.8 million, up 128.3% from the prior year.
- Total Liabilities rose to $634.7 million in Q1 2026 per VREOF's latest filing, from $509.8 million in the prior quarter.
- Over five years, Total Liabilities peaked at $634.7 million in Q1 2026 and troughed at $131.6 million in Q1 2022.
- A 5-year average of $256.5 million and a median of $204.9 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities climbed 6.16% in 2025, then surged 180.09% in 2026.
- Over 5 years, Total Liabilities stood at $155.7 million in 2022, then climbed by 27.99% to $199.3 million in 2023, then climbed by 12.04% to $223.3 million in 2024, then soared by 128.3% to $509.8 million in 2025, then climbed by 24.5% to $634.7 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $634.7 million, $509.8 million, and $432.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.12 Bn |
| 10 | Vireo Growth | 487.39 Mn | 345.09 Mn | 95.30 Mn | 831.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 634.70 Mn |
| Dec 31, 2025 | 509.80 Mn |
| Sep 30, 2025 | 432.61 Mn |
| Jun 30, 2025 | 390.76 Mn |
| Mar 31, 2025 | 226.61 Mn |
| Dec 31, 2024 | 223.30 Mn |
| Sep 30, 2024 | 204.87 Mn |
| Jun 30, 2024 | 217.24 Mn |
| Mar 31, 2024 | 213.46 Mn |
| Dec 31, 2023 | 199.31 Mn |
| Sep 30, 2023 | 184.52 Mn |
| Jun 30, 2023 | 173.88 Mn |
| Mar 31, 2023 | 160.70 Mn |
| Dec 31, 2022 | 155.72 Mn |
| Sep 30, 2022 | 156.85 Mn |
| Jun 30, 2022 | 144.83 Mn |
| Mar 31, 2022 | 131.65 Mn |
| Dec 31, 2021 | 123.96 Mn |
| Sep 30, 2021 | 113.25 Mn |
| Jun 30, 2021 | 56.43 Mn |